Clinical trial
A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF
NCT05060822 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 30, 2021
- Completion date
- December 11, 2026
- Enrollment
- 270 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.